Effect of Pioglitazone on Vascular Events in Post-stroke Cognitive Impairment: Post hoc Analysis of the IRIS Trial.

Prevention insulin resistance pioglitazone post-stroke cognitive impairment stroke recurrence treatment effect modification

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
26 Dec 2023
Historique:
medline: 27 12 2023
pubmed: 27 12 2023
entrez: 26 12 2023
Statut: aheadofprint

Résumé

In stroke patients with insulin resistance (IR), post-stroke cognitive impairment (PSCI) is associated with higher risk of recurrent stroke, but the effect of pioglitazone on that risk has not been explored. The goal of this study was to compare the secondary stroke prevention effect of pioglitazone against placebo in patients with versus without PSCI. We studied patients enrolled in the Insulin Resistance Intervention after Stroke (IRIS) trial with a post-stroke Modified Mini-Mental State Examination (3MS) cognitive assessment (mean time of assessment: 79 days post-stroke). We considered a baseline score of ≤ 88 on the 3MS to indicate global PSCI, and domain-specific summary scores in the lowest quartile to indicate attention, language, memory, orientation, and visuospatial impairments. In n=3338 patients with IR, the effect of pioglitazone vs. placebo on secondary stroke significantly differed by initial post-stroke global (interaction p = 0.0127) and memory impairment status (interaction p = 0.0003). Hazard ratios (HRs) were time-dependent such that, among those with either global or memory impairment, pioglitazone has an increasingly stronger protective effect at later timepoints. There was no statistically significant effect of pioglitazone among those without either global or memory impairment. The effect of pioglitazone vs. placebo on myocardial infarction (MI) also significantly differed by global impairment status (interaction p = 0.030). Pioglitazone was protective among those with global impairment (HR = 0.23; 95% CI: 0.08, 0.71)) but not among those without (HR = 0.88; 95% CI: 0.59, 1.31). These data indicate that pioglitazone treatment may be more effective at reducing risk of recurrent stroke and MI in stroke patients with PSCI. Simple cognitive testing 2 to 3 months post-stroke may identify patients for whom treatment would be most beneficial.

Sections du résumé

BACKGROUND. UNASSIGNED
In stroke patients with insulin resistance (IR), post-stroke cognitive impairment (PSCI) is associated with higher risk of recurrent stroke, but the effect of pioglitazone on that risk has not been explored. The goal of this study was to compare the secondary stroke prevention effect of pioglitazone against placebo in patients with versus without PSCI.
METHODS. UNASSIGNED
We studied patients enrolled in the Insulin Resistance Intervention after Stroke (IRIS) trial with a post-stroke Modified Mini-Mental State Examination (3MS) cognitive assessment (mean time of assessment: 79 days post-stroke). We considered a baseline score of ≤ 88 on the 3MS to indicate global PSCI, and domain-specific summary scores in the lowest quartile to indicate attention, language, memory, orientation, and visuospatial impairments.
RESULTS. UNASSIGNED
In n=3338 patients with IR, the effect of pioglitazone vs. placebo on secondary stroke significantly differed by initial post-stroke global (interaction p = 0.0127) and memory impairment status (interaction p = 0.0003). Hazard ratios (HRs) were time-dependent such that, among those with either global or memory impairment, pioglitazone has an increasingly stronger protective effect at later timepoints. There was no statistically significant effect of pioglitazone among those without either global or memory impairment. The effect of pioglitazone vs. placebo on myocardial infarction (MI) also significantly differed by global impairment status (interaction p = 0.030). Pioglitazone was protective among those with global impairment (HR = 0.23; 95% CI: 0.08, 0.71)) but not among those without (HR = 0.88; 95% CI: 0.59, 1.31).
CONCLUSIONS. UNASSIGNED
These data indicate that pioglitazone treatment may be more effective at reducing risk of recurrent stroke and MI in stroke patients with PSCI. Simple cognitive testing 2 to 3 months post-stroke may identify patients for whom treatment would be most beneficial.

Identifiants

pubmed: 38148372
doi: 10.1177/17474930231225568
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17474930231225568

Auteurs

Kat Schmidt (K)

Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC.

Melinda C Power (MC)

Department of Epidemiology, Milken Institute School of Public Health, George Washington University, Washington, DC.

Adam Ciarleglio (A)

Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Washington, DC.

Zurab Nadareishvili (Z)

Department of Neurology, School of Medicine and Health Sciences, George Washington University, Washington, DC & Stroke Center, Virginia Hospital Center, Arlington, VA.

Classifications MeSH